CGEM insider buying and SEC filings, explained
Cullinan Therapeutics, Inc. · CIK 1789972
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$927K
Planned sales (10b5-1)
$1.6M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 8, 2026 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 8,000 shares at about $21.57 ($173K), marked as a 10b5-1 plan trade. Holdings down 5% to 158,844 shares. | SEC filing Filed Sep 10, 2026 |
| Aug 13, 2026 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 30,000 shares at about $20.26 ($608K), marked as a 10b5-1 plan trade. Holdings down 16% to 162,844 shares. | SEC filing Filed Aug 14, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 8,000 shares at about $17.82 ($143K), marked as a 10b5-1 plan trade. Holdings down 5% to 162,844 shares. | SEC filing Filed Jul 7, 2026 |
| May 5, 2026 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 8,000 shares at about $14.62 ($117K), marked as a 10b5-1 plan trade. Holdings down 5% to 166,844 shares. | SEC filing Filed May 6, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 8,000 shares at about $15.68 ($125K), marked as a 10b5-1 plan trade. Holdings down 4% to 170,844 shares. | SEC filing Filed Mar 9, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 1,780 shares at about $14.14 ($25K), marked as a 10b5-1 plan trade. Holdings down 1% to 174,844 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 24, 2026 | Sale | Nadim Ahmed (CEO and Director) sold 13,515 shares at $14.47 ($196K). Holdings down 3% to 390,803 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 24, 2026 | Sale | Jeffrey Alan Jones (Chief Medical Officer) sold 4,582 shares at $14.47 ($66K). Holdings down 3% to 159,968 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 24, 2026 | Sale | Jacquelyn L. Sumer (Chief Legal Officer) sold 3,601 shares at $14.47 ($52K). Holdings down 3% to 128,089 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23–24, 2026 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 5,353 shares between Feb 23 and Feb 24 at about $14.31 ($77K), marked as a 10b5-1 plan trade. Holdings down 3% to 176,624 shares. | SEC filing Filed Feb 25, 2026 |
| Feb 20, 2026 | Sale | Mary Kay Fenton (CFO) sold 4,398 shares at $13.62 ($60K). Holdings down 3% to 126,380 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 23, 2026 |
| Feb 20, 2026 | Sale | Jeffrey Alan Jones (Chief Medical Officer) sold 4,982 shares at $13.62 ($68K). Holdings down 3% to 164,550 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 23, 2026 |
| Feb 20, 2026 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 11,742 shares at about $14.08 ($165K), marked as a 10b5-1 plan trade. Holdings down 6% to 181,977 shares. | SEC filing Filed Feb 23, 2026 |
| Feb 20, 2026 | Sale | Jacquelyn L. Sumer (Chief Legal Officer) sold 3,742 shares at $13.62 ($51K). Holdings down 3% to 131,690 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 23, 2026 |
| Feb 20, 2026 | Sale | Nadim Ahmed (CEO and Director) sold 16,381 shares at $13.62 ($223K). Holdings down 4% to 404,318 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 23, 2026 |
| Feb 12, 2026 | Sale | Jennifer Michaelson (Chief Scientific Officer) sold 416 shares at $12.03 ($5K). Holdings down <1% to 128,219 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Jan 22, 2026 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 4,000 shares at $12.30 ($49K), marked as a 10b5-1 plan trade. Holdings down 3% to 128,635 shares. | SEC filing Filed Jan 23, 2026 |
| Dec 23, 2025 | Sale | Nadim Ahmed (CEO and Director) sold 9,922 shares at $10.01 ($99K). Holdings down 2% to 420,699 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 29, 2025 |
| Dec 19, 2025 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 1,345 shares at about $10.01 ($13K), marked as a 10b5-1 plan trade. Holdings down 1% to 132,635 shares. | SEC filing Filed Dec 22, 2025 |
| Dec 18, 2025 | Sale | Jacquelyn L. Sumer (Chief Legal Officer) sold 3,480 shares at $9.67 ($34K). Holdings down 3% to 135,432 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 19, 2025 |
| Dec 18, 2025 | Sale | Jeffrey Alan Jones (Chief Medical Officer) sold 4,632 shares at $9.67 ($45K). Holdings down 3% to 169,532 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 19, 2025 |
| Dec 18, 2025 | Sale | Jennifer Michaelson (Chief Scientific Officer) sold 2,898 shares at $9.67 ($28K). Holdings down 2% to 133,980 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 19, 2025 |
| Dec 12–15, 2025 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 3,143 shares between Dec 12, 2025 and Dec 15, 2025 at about $12.23 ($38K), marked as a 10b5-1 plan trade. Holdings down 2% to 136,878 shares. | SEC filing Filed Dec 16, 2025 |
| Nov 24, 2025 | Planned (10b5-1) | Jennifer Michaelson (Chief Scientific Officer) sold 4,000 shares at $12.30 ($49K), marked as a 10b5-1 plan trade. Holdings down 3% to 138,004 shares. | SEC filing Filed Nov 25, 2025 |
21 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow CGEM in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.